IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 21-50 (2005)
Con tacts (Pharm): Chair man: Francesco
Balestrieri; Gen eral Con tact: F. Balestrieri
Sub sid iary of: Novartis, Swit zer land (100%)
HEXAL
Full Name: Hexal Aktiengesellschaft
Postal Ad dress: Postfach 12 63, D-83602
Holzkirchen
Street Ad dress: Industriestr. 25, D-83607
Holzkirchen
Tel: +49 8024 908 1127
Fax: +49 8024 908 1242
Email: ser vice@hexal.de
Home Page: www.hexal.de
De scrip tion: Prod uct ranges in clude: phar ma -
ceu ti cal prod ucts.
Con tacts (Pharm): Chair man: Hubert Mayr;
Com mer cial Op er a tions: Beate Bauer, Helmut
Plutat
Sub sid iary of: Novartis, Swit zer land (100%)
HEXAL GENTECH
Full Name: HEXAL Gentech Forschungs GmbH
Street Ad dress: Industriestrasse 25, D-83607
Holzkirchen
Tel: +49 8024 9080
Fax: +49 8024 9081290
Email: info@greinerbioone.com
Home Page: www.hexal-gentech.de
De scrip tion: Es tab lished 1998.
NOVARTIS
Full Name: Novartis Pharma GmbH
Postal Ad dress: Postfach, D-90327 Nuernberg
Street Ad dress: Roonstrasse 25, D-90429
Nuernberg
Tel: +49 911 273-0
Fax: +49 911 273-12653
Home Page: www.novartispharma.de
De scrip tion: Re searcher, de vel oper, dis trib u tor,
pro moter, sales/detailer. Prod uct ranges in clude:
phar ma ceu ti cal prod ucts (branded, pre scrip tion,
non-pre scrip tion), hos pi tal pharmaceuticals, oph -
thal mic prod ucts. Es tab lished 1997. 1,500 phar -
ma ceu ti cal em ploy ees in 2005. Di vi sions include:
Novartis Vaccines.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 501-1,000 (2005)
Con tacts (Pharm): Chair man: Em man uel
Pugimier; Com mer cial Op er a tions: Thomas
Kordick; Man u fac ture: John Man ning; Mar ket Re -
search: Roland Suess; Re search & De vel op ment:
Dr H. Wolf; Gen eral Con tact: Roland Suess
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 1,600-1,700 mil -
lion
Prod ucts (% of Sales by Lead ing 5): 45-50%
Ther a peu tic Classes (% of Sales by Lead ing
5): 60-65%
Dose Forms (% of Sales by Lead ing 5):
85-90%
Prin ci pal Prod ucts:
GLIVEC (antineoplastic other)
LUCENTIS (oc u lar antineovascularization prod -
uct)
CODIOVAN (an gio ten sin-II an tag o nist com bi na -
tion)
ZOMETA (bone cal cium reg u la tor)
MONO EMBOLEX (hep a rin)
Ther a peu tic Range:
antineoplastics 18%
renin-an gio ten sin sys tem agents 18%
ophthalmologicals 10%
musculoskeletal drugs other 8%
antithrombotic agents 7%
Lead ing Dose Forms:
coated tab lets 44%
vi als 17%
cap sules 10%
in fu sions 9%
tab lets 7%
NOVARTIS CON SUMER HEALTH
Full Name: Novartis Con sumer Health GmbH
Street Ad dress: Zielstattstrasse 40, D-81379
Muenchen
Tel: +49 89 78 77-0
Fax: +49 89 78 77-444
Email: info.muenchen@novartis.com
Home Page: www.novartis.de
De scrip tion: Dis trib u tor, pro moter,
sales/detailer. Dis trib utes, pro motes, sells/de tails
for other com pa nies. Prod uct ranges in clude:
phar ma ceu ti cal prod ucts (branded, non-pre scrip -
tion). Es tab lished 1997. 244 phar ma ceu ti cal
employees in 2007.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 51-100 (2007)
Con tacts (Pharm): Chair man: Ed ward Vlacich;
Mar ket Re search: Michaela Haertl
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 210-220 mil lion
Prod ucts (% of Sales by Lead ing 5): 65-70%
© 2009 IMS Health In cor po rated or its af fil i ates Page 171